SCHEMBL21050436

SCHEMBL21050436

COc1cc(N2C[C@H]3CC[C@@H](C2)[C@H]3NC(=O)O)ncn1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 1/20 0.45
▸ PSEN1 P49768 1/20 0.43
▸ PSEN2 P49810 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ APH1B Q8WW43 1/20 0.43
▸ NCSTN Q92542 1/20 0.43
▸ APH1A Q96BI3 1/20 0.43
▸ PSENEN Q9NZ42 1/20 0.43
▸ APP P05067 1/20 0.43
▸ ACACB O00763 6/20 0.38
▸ RIPK1 Q13546 2/20 0.38
▸ CHRM4 P08173 4/20 0.36
▸ CYP17A1 P05093 1/20 0.35
▸ TAF1 P21675 1/20 0.35
▸ CECR2 Q9BXF3 1/20 0.35
▸ BRD9 Q9H8M2 1/20 0.35
▸ PROKR1 Q8TCW9 1/20 0.35
▸ HCRTR1 O43613 2/20 0.35
▸ HCRTR2 O43614 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21050441 1.00 CYP2C19 (0.45) CYP2C19PSEN1PSEN2KCNH2APH1B
SCHEMBL21050439 1.00 CYP2C19 (0.45) CYP2C19PSEN1PSEN2KCNH2APH1B
SCHEMBL18971121 0.85 CYP2C19 (0.41) CYP2C19PSEN1PSEN2KCNH2APH1B
SCHEMBL18952582 0.85 CYP2C19 (0.41) CYP2C19PSEN1PSEN2KCNH2APH1B
SCHEMBL18952584 0.85 CYP2C19 (0.41) CYP2C19PSEN1PSEN2KCNH2APH1B
SCHEMBL21050474 0.85 CYP2C19 (0.41) CYP2C19PSEN1PSEN2KCNH2APH1B
SCHEMBL21093907 0.85 CYP2C19 (0.41) CYP2C19PSEN1PSEN2KCNH2APH1B
SCHEMBL21050462 0.85 PSEN1 (0.45) PSEN1PSEN2KCNH2APH1BNCSTN
SCHEMBL21050468 0.85 PSEN1 (0.45) PSEN1PSEN2KCNH2APH1BNCSTN
SCHEMBL21050466 0.85 PSEN1 (0.45) PSEN1PSEN2KCNH2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319314-B2 Phenoxytriazoles HOFFMANN-LA ROCHE INC. (US) 2022-05-03 — — US disclosed
US-20210309653-A1 PHENOXYTRIAZOLES HOFFMANN-LA ROCHE INC. (US) 2021-10-07 — — US disclosed
EP-3538516-B1 PHENOXYTRIAZOLES HOFFMANN LA ROCHE (CH) 2021-06-16 — — EP disclosed
US-10730881-B2 Fused pyrimidine derivatives HOFFMANN-LA ROCHE, INC. (US) 2020-08-04 — — US disclosed
US-20190177329-A1 FUSED PYRIMIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2019-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309653-A1 PHENOXYTRIAZOLES HTT, PSEN1, APP CYP2C19 3576/4885PSEN1 2/4885PSEN2 7/4885
US-10730881-B2 Fused pyrimidine derivatives APP, UPF1, PSEN1 CYP2C19 3050/4885PSEN1 3/4885PSEN2 10/4885
US-20190177329-A1 FUSED PYRIMIDINE DERIVATIVES APP, UPF1, PSEN1 CYP2C19 3050/4885PSEN1 3/4885PSEN2 10/4885
US-11319314-B2 Phenoxytriazoles HTT, APP, PSEN1 CYP2C19 3156/4885PSEN1 3/4885PSEN2 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback